Stada, the German pharmaceutical company backed by Bain Capital and Cinven, is preparing to launch an IPO on the Frankfurt Stock Exchange as early as this week.

If market conditions remain favorable, the firm is expected to issue an intention to float, marking one of Europe’s largest IPOs in recent years.

Stada, known for Grippostad cold medicine, Ladival sunscreen, and Silomat cough syrup, could be valued between €10bn and €12bn ($10.87bn-$13.05bn). The listing could position the company for inclusion in the MDax or potentially the DAX index, further elevating its market standing.

The IPO will be a significant test for Europe’s equity markets, which have faced subdued activity in recent months. If successful, Stada’s public debut could reignite investor confidence and set the tone for future private equity-backed listings in the region.